BrainSeq: Neurogenomics to Drive Novel Target Discovery for Neuropsychiatric Disorders

Christian R. Schubert, Patricio O'Donnell, Jie Quan, Jens R. Wendland, Hualin S. Xi, Ashley R. Winslow, Enrico Domenici, Laurent Essioux, Tony Kam-Thong, David C. Airey, John N. Calley, David A. Collier, Hong Wang, Brian Eastwood, Philip Ebert, Yushi Liu, Laura Nisenbaum, Cara Ruble, James Scherschel, Ryan Matthew SmithHui Rong Qian, Kalpana Merchant, Michael Didriksen, Mitsuyuki Matsumoto, Takeshi Saito, Nicholas J. Brandon, Alan J. Cross, Qi Wang, Husseini Manji, Hartmuth Kolb, Maura Furey, Wayne C. Drevets, Joo Heon Shin, Andrew E. Jaffe, Yankai Jia, Richard E. Straub, Amy Deep-Soboslay, Thomas M. Hyde, Joel E. Kleinman, Daniel R. Weinberger

Research output: Contribution to journalShort surveypeer-review

Abstract

We outline an ambitious project to characterize the genetic and epigenetic regulation of multiple facets of transcription in distinct brain regions across the human lifespan in samples of major neuropsychiatric disorders and controls. Initially focused on schizophrenia and mood disorders, the goal of this consortium is to elucidate the underlying molecular mechanisms of genetic associations with the goal of identifying novel therapeutic targets. The consortium currently consists of seven pharmaceutical companies and a not-for-profit medical research institution working as a precompetitive team to generate and analyze publicly available archival brain genomic data related to neuropsychiatric illness.

Original languageEnglish (US)
Pages (from-to)1078-1083
Number of pages6
JournalNeuron
Volume88
Issue number6
DOIs
StatePublished - 2015

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'BrainSeq: Neurogenomics to Drive Novel Target Discovery for Neuropsychiatric Disorders'. Together they form a unique fingerprint.

Cite this